[HTML][HTML] Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells

VD Dixit, EM Schaffer, RS Pyle… - The Journal of …, 2004 - Am Soc Clin Investig
VD Dixit, EM Schaffer, RS Pyle, GD Collins, SK Sakthivel, R Palaniappan, JW Lillard
The Journal of clinical investigation, 2004Am Soc Clin Investig
Ghrelin, a recently described endogenous ligand for the growth hormone secretagogue
receptor (GHS-R), is produced by stomach cells and is a potent circulating orexigen,
controlling energy expenditure, adiposity, and growth hormone secretion. However, the
functional role of ghrelin in regulation of immune responses remains undefined. Here we
report that GHS-R and ghrelin are expressed in human T lymphocytes and monocytes,
where ghrelin acts via GHS-R to specifically inhibit the expression of proinflammatory …
Ghrelin, a recently described endogenous ligand for the growth hormone secretagogue receptor (GHS-R), is produced by stomach cells and is a potent circulating orexigen, controlling energy expenditure, adiposity, and growth hormone secretion. However, the functional role of ghrelin in regulation of immune responses remains undefined. Here we report that GHS-R and ghrelin are expressed in human T lymphocytes and monocytes, where ghrelin acts via GHS-R to specifically inhibit the expression of proinflammatory anorectic cytokines such as IL-1β, IL-6, and TNF-α. Ghrelin led to a dose-dependent inhibition of leptin-induced cytokine expression, while leptin upregulated GHS-R expression on human T lymphocytes. These data suggest the existence of a reciprocal regulatory network by which ghrelin and leptin control immune cell activation and inflammation. Moreover, ghrelin also exerts potent anti-inflammatory effects and attenuates endotoxin-induced anorexia in a murine endotoxemia model. We believe this to be the first report demonstrating that ghrelin functions as a key signal, coupling the metabolic axis to the immune system, and supporting the potential use of ghrelin and GHS-R agonists in the management of disease-associated cachexia.
The Journal of Clinical Investigation